ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biologics

J&J to acquire Momenta Pharmaceuticals for $6.5 billion

by Ryan Cross
August 21, 2020 | APPEARED IN VOLUME 98, ISSUE 32

 

Johnson & Johnson has signed an agreement to purchase Cambridge, Massachusetts–based Momenta Pharmaceuticals for about $6.5 billion. The offer is a 70% premium on Momenta’s stock value before the announcement. J&J is interested in Momenta’s nipocalimab, an experimental antibody designed to target FcRn, a neonatal receptor associated with automimmune diseases. J&J says nipocalimab could be commercialized for multiple diseases, some of which could yield annual sales of over $1 billion.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment